◆英語タイトル:Pascal Biosciences Inc (PAS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8287
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Pascal Biosciences Inc (Pascal Biosciences), formerly BioMmune Technologies Inc is a biotechnology company that discovers and develops treatments in the field of immuno-oncology. The company develops targeted agents that enable the body’s own immune system to recognize and attack cancers, infections and autoimmune diseases. It advances research programs such as developing a therapeutic monoclonal antibody for treatment of b-cell precursor acute lymphoblastic leukemia; optimizing novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases. The company also conducts research on calcium channel blockers that modulates voltage-gated calcium channels for the signalling of immune system response and prevents transplant rejection. Pascal Biosciences is headquartered in Vancouver, British Columbia, Canada.
Pascal Biosciences Inc (PAS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pascal Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Biommune Enters into Agreement with University of British Columbia 10
Licensing Agreements 11
Pascal Biosciences Enters into Licensing Option Agreement with STC.UNM 11
Equity Offering 12
Pascal Biosciences Increases Size of Private Placement of Units for USD4 Million 12
Pascal Biosciences to Raise up to USD0.1 Million in Private Placement of Units 13
BioMmune Technologies Raises USD0.4 Million in Private Placement of Units 14
BioMmune Raise USD0.8 Million in Private Placement of Units 15
Acquisition 16
MC Partners Acquires bioMmune Advanced Technologies in Reverse Takeover Transaction 16
Pascal Biosciences Inc – Key Competitors 17
Pascal Biosciences Inc – Key Employees 18
Pascal Biosciences Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Strategy And Business Planning 20
May 09, 2017: Pascal Biosciences Creates Development Science Lab in Seattle WA 20
Corporate Communications 21
Jul 16, 2018: Pascal Biosciences names Julie M. Eastland as board director 21
Dec 05, 2017: Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell 22
Legal and Regulatory 23
Jun 18, 2018: Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration 23
Product News 24
Feb 21, 2018: Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells 24
Other Significant Developments 25
Mar 30, 2017: bioMmune Announces Name Change to Pascal Biosciences 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pascal Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pascal Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Biommune Enters into Agreement with University of British Columbia 10
Pascal Biosciences Enters into Licensing Option Agreement with STC.UNM 11
Pascal Biosciences Increases Size of Private Placement of Units for USD4 Million 12
Pascal Biosciences to Raise up to USD0.1 Million in Private Placement of Units 13
BioMmune Technologies Raises USD0.4 Million in Private Placement of Units 14
BioMmune Raise USD0.8 Million in Private Placement of Units 15
MC Partners Acquires bioMmune Advanced Technologies in Reverse Takeover Transaction 16
Pascal Biosciences Inc, Key Competitors 17
Pascal Biosciences Inc, Key Employees 18
List of Figures
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pascal Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8